1. Home
  2. LIN vs NVO Comparison

LIN vs NVO Comparison

Compare LIN & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Linde plc

LIN

Linde plc

HOLD

Current Price

$478.01

Market Cap

234.1B

Sector

Industrials

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$45.89

Market Cap

203.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIN
NVO
Founded
1879
1923
Country
United Kingdom
Denmark
Employees
N/A
69500
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.1B
203.2B
IPO Year
2017
2001

Fundamental Metrics

Financial Performance
Metric
LIN
NVO
Price
$478.01
$45.89
Analyst Decision
Strong Buy
Hold
Analyst Count
8
11
Target Price
$543.13
$51.00
AVG Volume (30 Days)
2.1M
11.3M
Earning Date
05-01-2026
05-06-2026
Dividend Yield
1.27%
3.19%
EPS Growth
7.27
N/A
EPS
8.13
N/A
Revenue
$33,986,000,000.00
N/A
Revenue This Year
$5.90
N/A
Revenue Next Year
$5.10
$3.70
P/E Ratio
$58.82
$13.60
Revenue Growth
2.97
N/A
52 Week Low
$387.78
$35.12
52 Week High
$548.20
$64.16

Technical Indicators

Market Signals
Indicator
LIN
NVO
Relative Strength Index (RSI) 38.57 43.37
Support Level $471.43 $45.62
Resistance Level $506.63 $46.92
Average True Range (ATR) 8.94 1.37
MACD -1.19 -0.27
Stochastic Oscillator 28.97 27.21

Price Performance

Historical Comparison
LIN
NVO

About LIN Linde plc

Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $34 billion in revenue in 2025.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: